Gilead’s Dan O’Day is pharma’s most charming executive — but with his deals falling apart, charm may not be enough. By Matthew Herper March 9, 2022. Reprints.

Gilead CEO Daniel O’Day received a compensation package of $23.7 million last year, which was a 5% boost on his $22.6 million pay from 2023.

Gilead Sciences Inc.GILD-0.20%decrease; red down pointing triangle has named industry veteran Daniel O’Day to take the helm and help the drug company revive sales and recover from a ...

Chairman and CEO Dan O'Day made $91 for every $1 in median Gilead employee compensation last year. Related Articles U.S. rolls back use of Vir's drug against new Covid variant ...

For all of 2022, Gilead CEO Daniel O’Day collected (PDF) $21.62 million, an 11% increase over the $19.23 million he scored in 2021. Salary accounted for about $1.7 million of O’Day’s payout.

Gilead Sciences' quest for a new CEO came to an end early Monday, with the struggling pharmaceutical company announcing that Roche Pharmaceuticals CEO Daniel O'Day will take the helm starting in ...

Gilead Sciences Inc (NASDAQ: GILD) is strongly positioned to “change the face of HIV” in 2025, according to its chairman and chief executive Daniel O’Day. He dubbed lenacapavir – the ...

Gilead has donated the entirety of its supply of remdesivir, O'Day said, which is roughly 1.5 million vials, or 100,000 to 200,000 treatment courses depending on the length of treatment.

And Gilead, which had about $25 billion in cash at the end of the last quarter, is “in an acquisitive mode,” he said. advertisement But that doesn’t mean O’Day is planning to pull the ...

Chairman and CEO Dan O'Day made $91 for every $1 earned by Gilead employees making the median salary. Gilead Sciences Inc. gave a slight bump in pay last year to CEO Dan O'Day, despite its ...